NasdaqGS:HALOBiotechs
Is It Too Late To Consider Halozyme Therapeutics (HALO) After A 36% One Year Gain?
If you are wondering whether Halozyme Therapeutics at around US$79.44 is still attractively priced or starting to look expensive, this article takes a closer look at what the current market price might be implying.
Over shorter horizons the stock has been mixed, with a 2.2% decline over the last 7 days, an 8.9% return over 30 days, a 13.0% return year to date, and a 36.3% return over 1 year. The 3 year and 5 year returns sit at 58.8% and 59.9% respectively.
Recent interest in Halozyme...